A
Amy A. Lubik
Researcher at University of British Columbia
Publications - 23
Citations - 1633
Amy A. Lubik is an academic researcher from University of British Columbia. The author has contributed to research in topics: Prostate cancer & Androgen deprivation therapy. The author has an hindex of 16, co-authored 23 publications receiving 1504 citations. Previous affiliations of Amy A. Lubik include Queensland University of Technology & Vancouver Prostate Centre.
Papers
More filters
Journal ArticleDOI
Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer
Jennifer A. Locke,Emma S. Tomlinson Guns,Amy A. Lubik,Hans Adomat,Stephen C. Hendy,Catherine A. Wood,Susan Ettinger,Martin E. Gleave,Colleen C. Nelson +8 more
TL;DR: In this article, the authors show that all enzymes necessary for androgen synthesis are expressed in prostate cancer tumors and some seem to be up-regulated during prostate cancer progression, leading to AR activation.
Journal ArticleDOI
The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer.
Martin C. Sadowski,Rebecca H. Pouwer,Jennifer H. Gunter,Amy A. Lubik,Ronald J. Quinn,Colleen C. Nelson +5 more
TL;DR: In this article, the authors compared the cellular and molecular effects of triclosan in a panel of eight malignant and non-malignant prostate cell lines to the well-known FASN inhibitors C75 and orlistat.
The fatty acid synthase inhibitor triclosan : repurposing an anti-microbial agent for targeting prostate cancer
Martin C. Sadowski,Rebecca H. Pouwer,Jennifer H. Gunter,Amy A. Lubik,Ronald J. Quinn,Colleen C. Nelson +5 more
TL;DR: Compared the cellular and molecular effects of triclosan in a panel of eight malignant and non-malignant prostate cell lines to the well-known FASN inhibitors C75 and orlistat, it is shown that inhibition of different partial catalytic activities of FASn activates different metabolic pathways.
Journal ArticleDOI
Insulin increases de novo steroidogenesis in prostate cancer cells.
Amy A. Lubik,Jennifer H. Gunter,Stephen C. Hendy,Jennifer A. Locke,Hans Adomat,Vanessa C. Thompson,Adrian C. Herington,Martin E. Gleave,Michael Pollak,Colleen C. Nelson +9 more
TL;DR: The hypothesis that the elevated insulin levels associated with therapeutic castration may exacerbate progression of prostate cancer to incurable CRPC in part by enhancing steroidogenesis is supported.
Insulin increases De Novo Steroidogenesis in prostate cancer cells
Amy A. Lubik,Jennifer H. Gunter,Brett G. Hollier,Ladan Fazli,Susan Ettinger,Nataly Stylianou,Hans Adomat,Stephen C. Hendy,Martin E. Gleave,Michael Pollak,Adrian C. Herington,Colleen C. Nelson +11 more
TL;DR: In this article, the effect of insulin on steroid synthesis in prostate cancer cell lines was examined by evaluating the effects of 10 nmol/L insulin on mRNA and protein expression of steroidogenesis enzymes and upregulated the insulin receptor substrate insulin-substrate 2 (IRS-2).